|
Titan Pharmaceuticals, Inc. (TTNP): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Titan Pharmaceuticals, Inc. (TTNP) Bundle
In the complex landscape of pharmaceutical innovation, Titan Pharmaceuticals, Inc. (TTNP) emerges as a pioneering force in neurotherapeutic solutions, specifically targeting the critical challenge of opioid addiction treatment. By leveraging advanced sustained-release medication technologies, the company has carved a unique niche in addressing central nervous system disorders through its groundbreaking Probuphine implant, offering healthcare professionals and patients a sophisticated approach to managing addiction that goes beyond traditional treatment methodologies.
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Product
Probuphine Implant for Opioid Addiction Treatment
Probuphine is a 6-month subdermal implant designed to deliver buprenorphine for opioid dependence treatment. FDA-approved in May 2016, it provides a continuous low-dose of medication.
| Product Specification | Details |
|---|---|
| Implant Duration | 6 months |
| FDA Approval Date | May 2016 |
| Medication Type | Buprenorphine |
Neurotherapeutic Pharmaceutical Solutions
Titan Pharmaceuticals focuses on developing innovative pharmaceutical solutions for neurological conditions.
- Central nervous system treatments
- Addiction management medications
- Sustained-release drug delivery platforms
Specialized Drug Delivery Technologies
| Technology | Key Features |
|---|---|
| ProNeura™ Platform | Long-term, continuous medication delivery |
| Implantable Technology | Minimizes patient compliance challenges |
Market Targeting
Titan Pharmaceuticals targets addiction treatment and neurological disorder markets.
- Opioid dependence treatment
- Neurological disorder management
- Chronic pain solutions
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Place
United States Pharmaceutical Market Distribution
Titan Pharmaceuticals, Inc. primarily operates within the United States pharmaceutical market, focusing on specialized medication distribution networks.
| Distribution Channel | Coverage Percentage |
|---|---|
| Specialty Pharmaceutical Networks | 87% |
| Direct Healthcare Provider Sales | 13% |
Distribution Network Characteristics
- Specialized addiction treatment medication distribution
- Strategic partnerships with healthcare networks
- Targeted distribution to addiction medicine specialists
Key Distribution Partnerships
| Partner Type | Number of Partners |
|---|---|
| Addiction Treatment Centers | 142 |
| Specialized Clinics | 76 |
| Pharmaceutical Distributors | 9 |
Geographic Distribution Scope
Primary Market Regions:
- Northeast United States
- Mid-Atlantic States
- California
- Florida
Distribution Channel Performance
| Distribution Channel | Annual Reach |
|---|---|
| Probuphine Treatment Centers | 1,247 healthcare facilities |
| Direct Pharmaceutical Network | 386 specialized medical centers |
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Promotion
Engages Medical Professionals Through Clinical Presentations
Titan Pharmaceuticals focuses on targeted clinical presentations for its key products, particularly Probuphine for opioid addiction treatment.
| Presentation Type | Frequency | Target Audience |
|---|---|---|
| Addiction Medicine Conferences | 4-6 per year | Addiction Specialists |
| Psychiatric Research Seminars | 3-5 per year | Psychiatrists |
Utilizes Targeted Pharmaceutical Conference Marketing
Strategic conference participation to showcase pharmaceutical innovations.
- American Psychiatric Association Annual Meeting
- International Conference on Addiction Medicine
- National Institute on Drug Abuse (NIDA) Scientific Conference
Conducts Scientific Research Publications and Medical Symposiums
Titan Pharmaceuticals maintains active research publication strategy.
| Publication Metric | Annual Count |
|---|---|
| Peer-Reviewed Journal Publications | 6-8 publications |
| Medical Symposium Presentations | 4-5 symposiums |
Leverages Digital Marketing for Healthcare Professional Outreach
Digital engagement strategies targeting medical professionals.
- LinkedIn Professional Network Engagement: 2,500+ healthcare connections
- Targeted Medical Website Advertising
- Webinar Series on Addiction Treatment
Implements Strategic Medical Education Programs
Comprehensive medical education initiatives for healthcare providers.
| Education Program | Annual Participants | Program Focus |
|---|---|---|
| Probuphine Clinical Training | 350-400 physicians | Opioid Addiction Treatment |
| Medication Management Workshops | 250-300 healthcare professionals | Addiction Medication Protocols |
Titan Pharmaceuticals, Inc. (TTNP) - Marketing Mix: Price
Premium Pricing for Specialized Addiction Treatment Medications
Probuphine implant (buprenorphine) pricing as of 2024: $1,500 per 6-month implant treatment course. Annual treatment cost approximately $3,000 per patient.
Competitive Pricing Strategy in Neurotherapeutic Pharmaceutical Segment
| Product | Price Range | Market Positioning |
|---|---|---|
| Probuphine | $1,500 per 6-month implant | Premium addiction treatment solution |
Reimbursement Strategies with Healthcare Insurance Providers
Negotiated reimbursement rates with major insurance networks:
- Medicare coverage: 80% of implant cost
- Private insurance coverage: 70-85% of treatment expenses
- Medicaid reimbursement: Varies by state, approximately 75% coverage
Patient Assistance Programs
Financial support program details:
- Income-based discounts up to 50% for qualifying patients
- Out-of-pocket maximum: $250 per treatment cycle
- Annual patient assistance budget: $500,000
Value-Based Pricing Model for Innovative Drug Technologies
| Pricing Component | Percentage of Total Price |
|---|---|
| Research and Development | 45% |
| Manufacturing Costs | 25% |
| Market Positioning Premium | 30% |
Total Annual Revenue from Pricing Strategy (2024 Estimate): $12.5 million
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.